Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $309,538.56 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 9,536 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.46, for a total value of $309,538.56. Following the completion of the transaction, the insider directly owned 190,838 shares in the company, valued at approximately $6,194,601.48. This trade represents a 4.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gina Mazzariello also recently made the following trade(s):

• On Thursday, July 9th, Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total value of $274,800.00.

Amylyx Pharmaceuticals Stock Down 1.6%

Shares of Amylyx Pharmaceuticals stock opened at $32.63 on Thursday. Amylyx Pharmaceuticals, Inc. has a 12 month low of $10.83 and a 12 month high of $41.14. The business has a fifty day simple moving average of $26.60 and a 200 day simple moving average of $19.26. The stock has a market cap of $3.64 billion, a PE ratio of -22.82 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $157,000. Arizona State Retirement System lifted its stake in Amylyx Pharmaceuticals by 9.5% in the second quarter. Arizona State Retirement System now owns 19,825 shares of the company’s stock valued at $356,000 after buying an additional 1,726 shares in the last quarter. Corient Private Wealth LP acquired a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $1,065,000. Alyeska Investment Group L.P. acquired a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $18,912,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amylyx Pharmaceuticals by 10.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock worth $3,114,000 after acquiring an additional 16,318 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Mizuho upped their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Citigroup increased their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Finally, Robert W. Baird upped their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $38.86.

Amylyx Pharmaceuticals Company Profile